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Most patients with relapsed non-Hodgkin’s lymphoma (NHL)
are incurable by current conventional treatment. High-dose
chemotherapy with stem cell support is effective only to patients
with chemosensitive disease (Armitage, 1993). Hence, new
treatment modalities are needed. Various immunotherapeutic
approaches, including the use of native monoclonal antibodies
(MoAbs), immunotoxins and radioimmunoconjugates, have been
investigated (for review see Multani and Grossbard, 1998).
MoAbs against the CD20 antigen given to patients with relapsed
B-cell NHL yielded response rates of about 30–50% (McLaughlin
et al, 1998). When conjugated to the b-emitting isotopes 131I (Press
et al, 1995; Kaminski et al, 1996) or 90Y (Knox et al, 1996),
responses in up to 86% were seen (Multani and Grossbard, 1998;
Liu et al, 1998). Radioimmunotherapy is dose-limited mainly by
haematological toxicity, unless stem cell support is given.
The a-emitter 211At has several favourable physical properties
compared to the currently used b-emitters. Thus the half-life (t1/2)
of 211At is only 7.2 h, whereas 131I and 90Y have half-lives of 8.0
days and 64 h, respectively. Alpha particles from 211At have an
average energy of 6.8 MeV and their range in soft tissue is only
55–80 mm, i.e. a few cell diameters. Because of the low range
of the a-radiation in tissues, need for patient shielding is greatly
reduced, allowing a-radioimmunotherapy to be given on an out-
patient basis (Larsen et al, 1999). Moreover, the high LET (linear
energy transfer) of 211At, about 97 keV mm–1, is close to the
optimum value for high RBE (relative biological effectiveness)
(Brown, 1986). Alpha emitters are also generally associated with
low oxygen enhancement ratio and virtual absence of dose–rate
effects (Barendsen et al, 1965; Hall, 1994). The short range of the
a-emitters implies that the radiation dose is delivered to the cell or
within its close vicinity. This fact, together with the targeting
ability of the MoAb, makes a-particle-emitting immunoconju-
gates attractive for radioimmunotherapy against dispersed cells
and micrometastases.
The present study was performed to explore the ability of
211At-rituximab to selectively inactivate NHL tumour cells with
acceptable bone marrow damage.
MATERIALS AND METHODS
Haematopoietic cells and lymphoma cell lines
Fresh mononuclear bone marrow (BM) cells from healthy volun-
teers were used. BM may contain various amounts of B-lympho-
cytes (CD20+), from < 1% up to 15–20%. Peripheral blood
progenitor cells (PBPC) were harvested in the recovery phase
following chemotherapy and G-CSF (in patients with other
diagnoses than NHL), and enriched CD34+ haematopoietic cells
(from PBPC) were used. Two B-cell NHL cell lines in exponential
growth, RAEL (high-grade) and K422 (low-grade) (Dyer et al,
1990), expressing the CD20 antigen, were studied.
Monoclonal antibody
A chimaeric anti-CD20 MoAb with murine variable regions and
human IgG1-kappa constant regions, IDEC-C2B8 or rituximab,
was used. This MoAb is marketed by IDEC Pharmaceutical
Corporation, San Diego CA and by Genentech Inc, San Francisco
CA in the USA under the name of Rituxan®, and in Europe by
Hoffmann-La Roche Ltd, Basel, Switzerland under the name
MabThera™. The CD20 antigen is expressed at high density on
malignant B-cells as well as normal B-lymphocytes, but not on
early B-cells and stem cells. Within the time-frame of 211At decay,
the CD20 antigen is virtually stable on the cell surfaces (Reff et al,
1994).
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Astatine-211 was produced in a cyclotron at the Department of
Physics, University of Oslo (Larsen et al, 1994 a) using the
209Bi(a, 2n) 211At reaction. Commercially available 125I (New
England Nuclear, Billerica MA, USA) was used for the iodine
labelling. Rituximab was radiolabelled with 211At and 125I and puri-
fied as previously described for other proteins (Larsen et al, 1994
b). The resulting radioimmunoconjugates, 211At-rituximab and 125I-
rituximab, were sterile-filtered prior to the biological experi-
ments, using a Millex-GV 0.22 mm filter (Millipore, Bedford MA,
USA).
In the present experiments the specific activity varied from
10–75 MBq mg–1. The specific binding fraction of 211At-labelled
rituximab was determined in a one-point assay. Cell-bound
radioimmunoconjugate was measured in triplicate after incubation
at room temperature for 1–2 h, using approximately 107 cells in
0.3 ml medium. An average of 36.4% of the labelled antibody
(range 17.3–54.1%) bound to antigen-positive RAEL cells,
whereas non-specific binding of ≤ 1.8% was measured on the
antigen-negative osteosarcoma cell line OHS. A binding fraction
of 36% in the one-point assay corresponds to an immunoreactive
fraction at infinite antigen excess (Lindmo et al, 1984) of about
50–60%, as verified experimentally (data not shown).
Cell killing activity of 211At-rituximab
Different amounts of 211At-rituximab were added to a fixed
concentration of 106 cells ml–1. Initial radioactivity concentrations
(kBq ml–1) in the test tubes were counted in a LKB Wallac 1277
Gammamaster gammacounter (Wallac Oy, Turku, Finland).
Two experimental series with different incubation time were
performed: A 1 h incubation series to study the efficacy of cell-
bound radioimmunoconjugate; and a 4 h incubation series to
simulate the prolonged circulation in vivo of IgG-type radio-
immunoconjugates. Four hours are similar to the effective half-life
of the radiopharmaceutical in the body, as indicated in mice exper-
iments. After the incubation, under soft stirring for 1 or 4 h, the
cells were washed in culture medium and centrifuged three times.
Then survival was measured in clonogenic assays, and compared
to that observed in the absence of radioactivity.
The number of clonogenic tumour cells remaining after
exposure to 211At-rituximab was assessed by a modified version
(Kvalheim et al, 1987) of the Courtenay and Mills soft agar clono-
genic assay (Courtenay and Mills, 1978). For evaluation of toxi-
city on haematopoietic cells the CFU-c (colony forming unit
cell) assay with METHOCULT H4433 medium (Stem Cell
Technologies Inc, Vancouver, Canada) was used. The toxicity of
the labelled MoAbs was also tested on more primitive (stem cell-
near) haematopoietic cells, using the LTC-IC (long-term culture
initiating cell) assay (Eaves et al, 1991). Briefly, the cells were
seeded on a pre-irradiated (20 Gy) human bone marrow stroma
mono-layer in the medium MYELOCULT H5100 (Stem Cell
Technologies Inc), supplemented with 50 mM hydrocortisone, and
cultured for 5 weeks before secondary culture in CFU-c assay.
Therapeutic gain
The relationship between the initial concentration of radioactiv-
ity (kBq ml–1) and clonogenic survival was, in the range test-
ed, best fitted by quadratic regression. The concentration of
211At-rituximab giving a survival of 10% or 37% (A10 or A37) was
calculated from the survival curves. A therapeutic gain factor
(TGF) for tumour cells relative to haematopoietic cells exposed to
211At-rituximab, was calculated using the following equation:
TGF37 = A37, BM/A37,tumour
Biodistribution
Biodistribution was studied in Balb/c mice. Astatine-211 and 125I
were examined in a ‘paired label’ fashion where 30 kBq of 125I-
labelled and 120 kBq of 211At-labelled rituximab in 100 ml were
co-injected into the tail vein of each animal. Approximately 4 mg
rituximab were injected per mouse. At various time-points three
mice were sacrificed, the organs were dissected out and weighed,
the radioactivity contents were measured and the percentage of
injected dose per g of tissue was determined.
Statistical analyses and curve estimations
SPSS 8.0, EXCEL 97 for Windows, and SigmaPlot (Scientific
Graphic Software, version 2, Jandel Corporation) were used in the
statistical analyses, plots and graphs. The input values for the
survival curves were calculated by the mean log10 anti-log of
surviving fractions for separate doses in the individual experi-
ments (presented in the Figures). Survival curves were fitted to the
data using quadratic regression of log10 survival. The 95% confi-
dence intervals (CI) of the survival curves were calculated using
log10 of the 95% CI from each point on the survival curves.
RESULTS
Cell-bound radioactivity
Cell-bound radioactivity (mBq cell–1), measured after 1 h incuba-
tion, is presented in Figure 1A for normal BM and CD34+ cells and
in Figure 1B for the RAEL cells. It is seen that, as expected,
much more radioactivity was bound to the tumour cells than to the
normal BM cells.
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Figure 1 Cell bound 211At-rituximab related to the initial activity
concentration. Radioactivity (mBq cell–1) bound to normal bone marrow cells
(BM) and to CD34+-selected haematopoietic cells (A) and to the lymphoma
cell line RAEL (B). Note differences in scale on the y-axisSurvival of lymphoma cells and haematopoietic cells
following exposure to 211At-rituximab
Clonogenic survival vs initial activity concentration of 211At-ritux-
imab is shown in Figure 2. The data in Figure 2A represent exper-
iments with BM cells from five different donors tested in CFU-c,
four of them also examined in LTC-IC assays. In addition, one
experiment with enriched CD34+ cells is included in the figure. In
Figure 2B four individual experiments with RAEL cells are
shown. Comparison of Figure 2A and 2B (1 h measurements)
demonstrates a highly significant, favourable survival of the BM
cells compared to the malignant RAEL cells. From the survival
curves the following mean A10 values were estimated: 50.0 kBq
ml–1 for BMCFU-c, 39.1 for BMLTC-IC, 203.5 for CD34+
CFU-c and 9.0
for RAEL. An initial activity concentration of 50 kBq ml–1 yielded
corresponding log cell kill values of 1.00, 1.24, 0.20 and 4.13. In
Table 1 the values are given with 95% CI.
BM cells tested in LTC-IC were separated from cells in standard
CFU-c assay just before plating. Hence, these stem cells were
exposed to the same crossfire irradiation from B-cells in the pellets
before seeding. The experiments showed a tendency of higher
toxicity on BM evaluated in LTC-IC as compared to CFU-c assay,
but the differences were not significant, P = 0.36 (paired samples
t-test, two-tailed). In contrast, the toxicity towards CD34+
cells was lower for the tested initial concentrations of activity
(Figure 2A).
In Figure 2C and 2D the results of 4 h measurements are shown.
Since 4 h incubation may reflect a more realistic time schedule
with regard to the effective half-life of 211At-rituximab adminis-
tered to patients, the study was extended with these series. The
data in Figure 2C and 2D represent three individual experiments
for each tumour cell line, BM from three different donors and two
PBPC products. Again the 211At-rituximab was found to be far
more toxic to the tumour cells than to the haematopoietic cells.
However, neither between BM and PBPC nor between the two
tumour cell lines were significant differences found. Calculations
from the survival curve parameters give the following mean A10
values (kBq ml–1): 22.8 for BM, 5.6 for RAEL and 4.3 for K422.
Such low survival level was not observed for PBPC in the given
range of initial activity concentrations. At an initial activity
concentration of 25 kBq ml–1, the mean log cell kills were 1.01 for
BMCFU-c, 0.61 for PBPCCFU-c, 3.39 and 3.54 for RAEL and K422,
respectively (Table 1).
The amounts of radioactivity added in this study correspond to a
rituximab concentration of less than 8 mg ml–1. In a control experi-
ment with unlabelled rituximab at similar concentrations as used
with the radioimmunoconjugate, no significant effect on survival,
neither of the RAEL nor the BM cells, was observed (data not
shown). This indicates that the radioisotope was essential for the
effectiveness of 211At-rituximab in the present experiments. The
concentrations used represent less than 3.5% of the serum concen-
tration obtained in clinical trails using therapeutic doses of native
rituximab (McLaughlin et al, 1998).
Anti-CD-20 a-particle-radioimmunotherapy 1377
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Figure 2 Clonogenic survival of haematopoietic cells and lymphoma cells
related to initial concentration of radioactivity (kBq ml–1) of 211At-rituximab.
Incubation times were 1 h (A and B) and 4 h (C and D). The logarithmic
mean surviving fractions from each experiment (3–9 parallels at each point),
and the quadratic regression lines are marked. The open symbols with
arrows (B and D) represent points where no colonies were observed at the
highest seeded cell concentration. (A) BM, evaluated in both CFU-c and
LTC-IC assays, as well as CD34+ cells plated in CFU-c assay, are compared,
while in (B) the surviving fractions of RAEL are shown. (C) Survival of BM
and PBPC following 4 h incubation and (D) the two tumour cell lines, RAEL
and K422.
Table 1 A10 valuesa and log cell killsa following exposure to 211At-rituximab
Cells BMCFU-c BMLTC-IC CD34+
CFU-c PBPCCFU-c RAEL K422
Incubation time – 1 h
A10 (kBq ml–1) 50.0 39.1 203.5 – 9.0 –
(45.4–56.4) (27.9, 45.4) (167.1, –) (7.7, 9.8)
Log cell kill 1.00 1.24 0.20 – 4.13 –
at 50 kBq ml–1b (0.91–1.10) (1.09, 1.61) (0.12, 0.28) (3.95–4.50)
Incubation time – 4 h
A10 (kBq ml–1) 22.8 – – – 5.6 4.3
(12.6, –) (5.5–6.0) (4.1–4.6)
Log cell kill 1.01 – – 0.61 3.39 3.54
at 25 kBq ml–1b (0.86–1.14) (0.44–0.71) (3.18–3.96) (3.38–3.70)
aMean (95%CI); binitial activity concentration1378 E Aurlien et al
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Therapeutic gain
Both 1 h and 4 h incubation with 211At-rituximab gave favourable
therapeutic windows between tumour cells and haematopoietic
cells. The average TGF37 ± SD, is presented in Table 2. In the 1 h
series TGF37 between RAEL and BMCFU-c was 5.2 in average.
TGF37 for tumour cells vs BMCFU-c in the 4 h series were 2.3 for
RAEL and 3.0 for K422.
Biodistribution in mice
Table 3 presents the tissue distribution of 211At-rituximab and 125I-
rituximab in eight organs of the mice, within a time-frame of
1–23.5 h. The biodistribution of 211At-rituximab was similar
compared to that of 125I-rituximab, and revealed the general char-
acteristics of IgG radiolabelled MoAbs, i.e. high initial activity
levels in blood and blood-rich tissues.
DISCUSSION
The reported experiments were designed to assess targeted
a-emitter exposure to dispersed B-lymphoma cells and
haematopoietic progenitor cells.
The normal bone marrow cells generally showed a low sensi-
tivity following exposure to 211At-rituximab. BM contains various
amounts of B-lymphocytes, ranging from < 1% up to 20%, which
may explain the considerable variation in cell-bound activity
observed in different experiments. The difference in toxicity on
the BM cells, reflected in the survival curve (Figures 2A and 2C),
could possibly be explained by crossfire irradiation of the antigen-
negative clonogenic cells from B-cells in the pellets before
seeding. This is further supported by the very low toxicity
observed with CD34+-enriched cells, which had low binding of
211At-rituximab, due to the virtual absence of B-cells in this cell
population. Furthermore, PBPC products, which contain about
0.5–1% B-cells, also showed a trend towards lower cytotoxicity
from the radioimmunoconjugate compared to BM, although the
difference was not statistically significant. Neither was the
survival significantly different between BM cells tested
concurrently in the CFU-c and the LTC-IC assay.
Astatine-211-labelled rituximab was highly cytotoxic to both
high- and low-grade NHL cells when measured after 4 h incuba-
tion, and no significant difference in survival between the two cell
lines was found (Figure 2D).
In our experiments, A37 following 1 h incubation was 3.8 and
19.5 kBq ml–1 for RAEL and BMCFU-c, respectively, whereas the
calculated value for CD34+ cells was as high as 100.9 kBq ml–1.
Hence, A37 for CD34+ cells was almost identical to the values
previously reported for human cell lines exposed to non-specific
211At-BSA (bovine serum albumin) (Larsen et al, 1994a).
The biodistribution profile indicated that the quality of the
immunoconjugate had not been significantly reduced by labelling
with 211At and also that the stability of the conjugate in vivo was
adequate. As with 131l-labeled compounds a blocking agent should
be used for therapeutic purposes to minimize radiation dose to the
thyroid for 211At (Larsen et al, 1998).
The current study confirms previous reports indicating that
a-emitting immunoconjugates may have selective anti-tumour
effect. One study by Harrison and Royle (1987) used 211At conju-
gated to a T-cell antibody (OX7) to treat a T-cell lymphoma in
mice and increased the median survival time of mice and probably
‘cured’ more than half of the animals (Harrison and Royle, 1987).
Later Behr and colleagues (1999) compared the therapeutic
efficacy and toxicity of the a-emitter  213Bi with that of the
b-emitter 90Y, linked to a monovalent Fab¢ fragment, in a human
colonic cancer xenograft model in nude mice (Behr et al, 1999).
They concluded that radioimmunotherapy with a-emitters may
be therapeutically more effective than conventional b-emitters.
Recently pharmacokinetics and dosimetry of a 213Bi-labelled anti-
CD33-antibody in patients with leukaemia was reported (Sgouros
et al, 1999).
Clinical studies with radioimmunoconjugates (131I and 90Y) in
lymphomas have mainly involved murine MoAbs. Using a
chimeric MoAb like rituximab in radioimmunotherapy could
Table 2 Therapeutic gain factor at 37% cell survival (TGF37)a following exposure to 211At-rituximab
RAEL to K422 to
Incubation time BMCFU-c BMLTC-IC CD34+
CFU-c PBPCCFU-c BMCFU-c PBPCCFU-c
1 h 5.2 ± 0.7 4.2 ± 1.2 26.8 ± 3.9 – – –
4 h 2.3 ± 0.5 – – 5.0 ± 2.8 3.0 ± 0.7 6.5 ± 3.7
aMean ± SD
Table 3 Biodistributiona of 211At- and 125I-rituximab in mice
1 h 3.5 h 10.75 h 23.5 h
Tissue 211At-rituximab 125I-rituximab 211At-rituximab 125I-rituximab 211At-rituximab 125I-rituximab 211At-rituximab 125I-rituximab
Blood 36.2 ± 2.9 37.9 ± 2.1 32.9 ± 1.9 32.3 ± 2.0 27.1 ± 1.2 28.5 ± 0.6 17.4 ± 1.4 20.1 ± 2.0
Lung 15.5 ± 3.6 15.7 ± 3.8 13.4 ± 1.5 12.6 ± 2.0 11.6 ± 1.3 11.1 ± 1.2 8.5 ± 1.9 8.7 ± 1.8
Liver 11.5 ± 1.5 13.0 ± 1.7 9.5 ± 1.0 10.5 ± 0.8 6.7 ± 0.7 8.2 ± 1.2 4.4 ± 1.2 4.2 ± 3.4
Heart 10.5 ± 0.8 10.1 ± 0.8 10.2 ± 0.9 11.2 ± 1.2 8.9 ± 1.3 8.4 ± 0.5 6.8 ± 0.9 6.9 ± 0.9
Spleen 8.1 ± 2.7 8.7 ± 1.9 7.9 ± 0.9 7.6 ± 0.7 7.3 ± 0.6 7.2 ± 0.2 4.6 ± 0.8 5.0 ± 0.6
Kidney 7.9 ± 0.8 9.1 ± 0.8 8.5 ± 1.1 9.0 ± 1.2 6.5 ± 1.3 7.7 ± 0.9 4.1 ± 0.1 5.2 ± 0.6
Muscle 1.0 ± 0.4 1.2 ± 0.3 1.6 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.8 ± 0.1 1.5 ± 0.3 1.8 ± 0.3
Bone 2.8 ± 0.7 2.9 ± 0.3 2.8 ± 0.5 2.9 ± 0.1 3.0 ± 0.2 3.2 ± 0.2 2.0 ± 0.4 2.9 ± 0.2
aValues expressed as % of i.v. injected dose of 211At- and 125I-rituximab per gram tissue, mean ± SDAnti-CD-20 a-particle-radioimmunotherapy 1379
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strongly reduce HAMA (human anti-mouse antibody) responses
in patients. However, the prolonged biological half-life of the
humanized MoAbs could cause problems with increased radiation
dose to normal tissues, and hence a decreased therapeutic index,
when isotopes with longer half-life (days) are utilized (Bruland,
1995; Multani and Grossbard, 1999). The use of a relatively short-
lived isotope like 211At will make those differences in biological
half-life less relevant.
As pointed out, 211At also has several advantages from a
radiation-protection point of view. More than 99% of its radiation
energy is from a-particles. The short half-life (7.2 h) could reduce
the hospitalization time, and the short tissue-range of the a-parti-
cles (maximum 80 mm) would simplify the protection of the staff
and environment (Larsen et al, 1999).
A BM progenitor cell survival of 5% should be sufficient for
recovery without stem-cell support. This survival level of BMCFU-c
was observed at an initial activity concentration of 70.3 kBq ml–1
following 1 h incubation. The corresponding log cell kill of RAEL
was as high as 4.8. Consequently there may be a significant thera-
peutic window if non-myeloablative doses of 211At-rituximab are
explored clinically.
In conclusion, our study shows that rituximab labelled with 211At
exerts selective cytotoxicity to NHL tumour cells in vitro. The
effect of the radioimmunoconjugate will now be investigated in
patients with relapsed B-cell lymphomas.
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